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An Australian Twin Study of Cannabis and Other
Illicit Drug Use and Misuse, and Other
Psychopathology
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Nicholas G. Martin2
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Cannabis is the most widely used illicit drug throughout the developed world and there is consistent
evidence of heritable influences on multiple stages of cannabis involvement including initiation of use
and abuse/dependence. In this paper, we describe the methodology and preliminary results of a large-
scale interview study of 3,824 young adult twins (born 1972–1979) and their siblings. Cannabis use was
common with 75.2% of males and 64.7% of females reporting some lifetime use of cannabis while 24.5%
of males and 11.8% of females reported meeting criteria for DSM-IV cannabis abuse or dependence. Rates
of other drug use disorders and common psychiatric conditions were highly correlated with extent of
cannabis involvement and there was consistent evidence of heritable influences across a range of cannabis
phenotypes including early (≤15 years) opportunity to use (h2 = 72%), early (≤16 years) onset use (h2 =
80%), using cannabis 11+ times lifetime (h2 = 76%), and DSM abuse/dependence (h2 = 72%). Early age
of onset of cannabis use was strongly associated with increased rates of subsequent use of other illicit
drugs and with illicit drug abuse/dependence; further analyses indicating that some component of this
association may have been mediated by increasing exposure to and opportunity to use other illicit drugs.
 Keywords: Cannabis, twin, Comorbidity, Illicit drugs
Cannabis is the most widely used illicit drug in most devel-
oped countries (Degenhardt et al., 2011; Dennis et al., 2002;
Hall & Degenhardt, 2007). Current (2010) US estimates
suggest that 43.8% of 12th grade students have ever used
cannabis, 34.8%have used it in the last year, and 21.4%have
used it in the past month (Johnston et al., 2011). Slightly
higher figures have been reported for Australia: 56.6% of
17-year-old males and 54.2% of 17-year-old females re-
ported lifetime use of cannabis while 6.8% of male and
3.1% of female 12–17 year olds reported using the drug on
at least 40 occasions in the past year (Lynskey et al., 1999).
While many people who have used cannabis do so only
infrequently, a substantial minority use cannabis heavily
and experience a range of adverse consequences as a re-
sult and the potential of cannabis to be associated with
abuse and dependence is recognized in both the Diag-
nostic and Statistical Manual of Mental Disorders (DSM)
(American Psychiatric Association, 1994) and the Interna-
tional Classification of Diseases (World Health Organiza-
tion, 2007). The estimated prevalence of cannabis depen-
dence has varied widely with lifetime prevalence estimated
in the region of 0.9–2.2% of the adult population (Kendler
& Prescott, 1998; Perkonigg et al., 1999) while, seemingly
paradoxically, the 12-month prevalence of cannabis depen-
dence has been estimated to be as high as 9% (Chen et al.,
1997; Coffey et al., 2002; Fergusson & Horwood, 2000;
Teesson et al., 2002).
Heritability of Cannabis Use and Cannabis Use
Disorders
In recent years there has been a growing accumulation of
studies examining the heritability of cannabis-related phe-
notypes. Verweij et al. (2010) identified 28 studies report-
ing the heritability of cannabis use initiation and 27 studies
reporting the heritability of problematic cannabis use (typ-
ically abuse or dependence symptomatology). Summing
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results from these studies using meta-analytic techniques,
they reported that for initiation of cannabis use, 48% of
variance in liability in males and 40% of the variance in
females could be attributed to additive genetic factors while
the estimates for problematic cannabis use were 51% and
59%, respectively. Modest genetic influences on availability
of cannabis have also been reported (Gillespie et al., 2007).
Comorbidity
Cannabis use and cannabis use disorders are frequently
comorbid with other aspects of substance use and psychi-
atric disorders (Kandel et al., 2001). Limited genetically
informative research has suggested that a substantial co-
morbidity can be explained by common or shared genetic
factors. For example, conduct disorder and other external-
izing problems often co-aggregate with early cannabis use
and cannabis use disorders (Deas & Brown, 2006; Meyers &
Dick, 2010). Additionally, Shelton and colleagues (Shelton
et al., 2007) found that genes influencing conduct problems
during childhoodweremodestly but significantly correlated
with subsequent liability to cannabis use and misuse. Sim-
ilarly, Lynskey et al. (2004) reported a significant genetic
correlation between cannabis use disorders and major de-
pressive disorder (MDD), and suggested that previously
documented associations between early onset cannabis use
and MDD could be largely attributed to the influence of
shared genetic risk factors.
Gateway Effects
One of the most enduring controversies in drug research
and policy concerns whether early cannabis use predisposes
to the use of other drugs such as cocaine and heroin (Hall &
Lynskey, 2005; Kandel, 2002; Kandel & Faust, 1975; Morral
et al., 2002). Several researchers have reported strong asso-
ciations between early cannabis use and subsequent use of
other drugs, even after control for a wide range of poten-
tially confounding covariates (Fergusson&Horwood, 2000;
Fergusson et al., 2002; Kandel et al., 1992). However, these
analyses may not have adequately controlled for important
family background factors, including potential genetic in-
fluences, predisposing to both early cannabis use and later
use of other illicit drugs. In an earlier study of this issue
employing a discordant twin design we reported, contrary
to expectations that, relative to their nonearly using co-
twins, individuals who commenced cannabis use prior to
age 17 had significantly elevated rates of illicit drug use and
illicit drug dependence, suggesting that the observed asso-
ciations between early onset cannabis use and later illicit
drug use cannot be solely attributed to genetic and shared
environmental liabilities (Lynskey et al., 2003). Further, in
a replication of this study employing sample of Dutch twins
discordant for early onset use, we again found elevated rates
of subsequent illicit drug use in individuals who reported
early onset cannabis use, relative to their nonearly using
co-twin (Lynskey et al., 2006) indicating that the relative
tolerance toward marijuana use in the Netherlands did not
modify the links between cannabis and other illicit drug use.
In 2005, we received a 5-year independent investiga-
tor grant (R01) from National Institute on Drug Abuse
(DA18267), the principal aims of which were to exam-
ine the links between age of onset of cannabis use and
risks for the subsequent development of other drug use and
abuse/dependence. A key goal of the current study was to
collect extensive data on patterns of early onset cannabis use
and subsequent use and abuse/dependence on other illicit
drugs to provide a rigorous test of the gateway hypothesis
within a genetically informative research design.
Current Aims
Against this general background, aims of this study were
to conduct a new, large-scale epidemiological survey of a
national sample of Australian twins, previously never in-
terviewed, to collect detailed phenotypic information on
patterns of cannabis use and cannabis-related symptoma-
tology, associated use, abuse, and dependence on both licit
and illicit drugs; psychiatric comorbidity including conduct
disorder,MDD, social phobia, and panic disorder; child and
family circumstances including opportunity to use drugs,
exposure to interparental conflict, parenting practices, peer
affiliations, and adult role transitions. Below we describe
the methodology of this study and provide a series of re-
sults detailing:
(a) The extent of cannabis involvement in this sample.
(b) The comorbidity between cannabis involvement and
psychiatric morbidity.
(c) Associations between age of onset of cannabis use and
subsequent risks of other illicit drug use and drug
abuse/dependence (including tobacco and alcohol).
(d) The heritability of selected cannabis-related pheno-
types including: early opportunity touse cannabis, early
onset cannabis use, lifetime use of cannabis on 11 or
more occasions, and meeting criteria for a DSM diag-
nosis of cannabis abuse or dependence.
Method
Sample
At the time this studybegan (2005), the volunteerAustralian
Twin Registry (ATR) had enrolled a total of 4,131 twin pairs
born 1972–1979. Attempts to recruit these individuals to
participate in the current cannabis study were made using
two-tiered process, as required by the ATR’s ethics com-
mittee: first, the ATR contacted twins (by mail and subse-
quently by telephone) and asked if they were willing to have
their name and contact details forwarded to the Queens-
land Institute of Medical Research (QIMR) for potential
participation in an interview-based study of substance use
and mental health. Contact details of those consenting
to such were then forwarded to QIMR who made
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TABLE 1
Distribution of Targeted Subjects and Those Completing the Interview and Questionnaire Phases of the
Study
N in study Completed IV +Q Completed IV (includes partials) Completed Q
Sex Males 2,020 1,224 1,389 1,257
Females 2,958 2,330 2,435 2,368
Total Rs 5,004 3,554 3,824 3,625
Twins Male twins 1,418 1,047 1,180 1,074
Female twins 2,368 2,083 2,168 2,112
Total twins 3,786 3,130 3,348 3,186
Siblings Male siblings 602 177 209 183
Female siblings 590 247 267 256
Total siblings 1,218a 424 476 439
Pairs Pairs 1,525 1,116 1,233 1,151
Both pairs 3,050 2,232 2,466 2,302
One of pair only NA 329 250 304
Singleton 736 569 632 580
Siblings 1,218 424 476 439
Total Respondents 5,004 3,554 3,824 3,625
Siblings with consent to be
approached
849
Note: aSome numbers in sex breakdown do not sum to total as sex of some siblings is unknown.
separate attempts to (re)contact potential subjects, explain
the purposes of the study to them, and enroll them in the
study. Due to a lower than anticipated initial response from
enrolled twins, efforts were made in the final phases of data
collection to identify and recruit siblings of participating
twins as there are well known increases in statistical power
for genetically informative research design including three
or more related individuals.
The ATR approached 7,850 twins born between 1972
and 1979, of these 3,786 twins consented to participate,
1,971 declined and the reminder gave passive refusals (5
attempts/calls without reaching respondent) or did not re-
spond. In addition, upon interview with the twins, 1,218
siblings were eligible for participation and 849 were re-
cruited of which 424 siblings completed both the interview
and questionnaire. Siblings were recruited by QIMR staff
andat least 10–15attemptsweremade to contact siblingsbe-
fore classifying them as passive refusals. Respondents were
also contacted weekly, over a period of 3 months, regard-
ing the questionnaire. On completion of both the interview
and questionnaire, all respondents received a $50 gift card.
Table 1 provides the distribution of twins and siblings, by
sex and paired status, who participated in the interview and
questionnaire components of the project.
The final sample comprised 3,824 participants from a
target sample of 5,004 individuals who provided with con-
sent for QIMR to approach them and included: 3,348 twin
individuals, including: (a) 976 monozygotic female (MZF),
with 398 pairs and 180 unpaired twins; (b) 490 monozy-
gotic male (MZM), with 173 pairs and 144 unpaired twins;
(c) 741 dizygotic female (DZF), with 305 pairs and 131
unpaired twins; (d) 373 dizygotic male (DZM), with 118
pairs and 137 unpaired twins; and (e) 746 dizygotic oppo-
site sex (DZOS), with 231 pairs and 284 unpaired twins.
There were 22 twins with undetermined zygosity and 476
nontwin siblings.
Assessment Protocol
The assessment protocol was based on the semi-structured
assessment of the genetics of alcoholism (Australian ver-
sion; SSAGA-OZ) and administered using a computer-
administered telephone interview (Bucholz et al., 1994;
Heath et al., 1997) used in a previous ‘1989’ cohort of Aus-
tralian twins born between 1964 and 1971 (Knopik et al.,
2004). This instrument obtains full diagnostic criteria for
cannabis and other illicit drug abuse and dependence. In
addition, we assessed specific aspects of experience with
cannabis and other illicit drugs, including exposure oppor-
tunity, initial subjective reactions to cannabis and compo-
nents of cannabis withdrawal, and full DSM-IV diagnostic
criteria for a number of other diagnoses (MDD, childhood
conduct disorder, alcohol and nicotine dependence, panic
disorder). The SSAGA, from which this interview assess-
ment was derived, has been shown to have good reliability
and validity as a measure of standardized DSM-IV diag-
nostic criteria for a range of conditions including alcohol
abuse and dependence, nicotine dependence, MDD, and
antisocial personality disorder (Bucholz et al., 1994).
In addition, respondents were requested to complete a
brief questionnaire which included questions on physical
health, personality, and other measures. These items were
assessed using a questionnaire rather than during the in-
terview to reduce the length of the interview. Respondents
were offered twomethods for completing the questionnaire
survey: either by completing a ‘paper and pen’ survey and
returning it to QIMR via post or by completing the sur-
vey over the Internet (after logging on with a unique ID
and password, supplied by QIMR). Response rates for the
questionnaire were excellent: 93% of those interviewed also
completed the questionnaire, with 75% of those opting to
complete the Internet version of the questionnaire.
The assessment protocol is summarized in Table 2 and
key features are highlighted below.
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TABLE 2
Summary of Domains Assessed
Cannabis use Behavioral inhibition
Age of first use opportunity Major depression
Age at initiation of cannabis use Suicidal ideation
Initial reactions to cannabis use Suicide attempt
Weekly use Neuroticism (NEO)
Daily use Social phobia (DSM)
Cannabis use disorders Panic disorder (DSM)





Other illicit drug use Behavioral undercontrol
Age of first use opportunity Childhood conduct disorder
Lifetime use Antisocial personality disorder
Age of onset Childhood hyperactivity
Frequency of use (when used most) Childhood inattention
Abuse Extraversion (NEO)
Dependence Novelty seeking (TPQ)
Tobacco use Sociodemographic
Initiation of smoking Household income
First reactions to tobacco Parental educational levels
Transition to weekly smoking (age) Parental marital status & history
Transition to daily smoking (age) Family structure & rearing history





Maximum cigarettes in single day Academic achievement
Tobacco dependence (DSM-IV) School grades
Alcohol use Educational history/status
Initiation of alcohol use Family ‘environment’ variables
First reactions to alcohol Perceived parental conflict
Frequency of alcohol use Perceived parent–child conflict
Amounts consumed (current and
maximum)




Parent–child relations — parental
involvement
Alcohol dependence (DSM-IV) Parental coldness, overprotection
Parental alcohol use/problems Parental major depression
Proximal risk factors Parental alcohol dependence
Peer behaviors Parental discipline
Perceived peer Smoking Risk modifiers
Perceived best friend’s smoking Parent–child relations — parental
controlPerceived peer alcohol use
Perceived best friend’s alcohol use
Perceived peer delinquent
behavior
Perceived peer illicit drug use
Perceived co-workers tobacco,
alcohol, and illicit drug use
DSM-IV Cannabis Abuse
The reliability and validity of DSM cannabis abuse diag-
noses derived from the SSAGA are comparable to estimates
of the reliability of abuse diagnoses derived from other in-
struments. Thus, this unreliability likely reflects problems
with the conceptualization of abuse diagnoses (Hasin &
Paykin, 1999).
DSM-IV Cannabis Dependence
Cannabis dependence was assessed using SSAGA, supple-
mented by detailed questions, based on those described by
Budney et al. (Budney et al., 2004; Budney&Hughes, 2006),
to assess potential symptoms of withdrawal. A lifetime di-
agnosis was obtained by endorsement of 3 of 7 (including
withdrawal) criteria clustering within a single 12-month
period. However, as the DSM-5 operationalization of with-
drawalwasunknownat the timeof interview, fordiagnosing
dependence, withdrawal was coded as endorsement of 2 or
more of 7 criteria or withdrawal relief.
Other Substance use, Abuse, and Dependence
Comprehensive information on patterns of substance use
and symptoms of DSM-IV abuse and dependence was as-
sessed using the SSAGA and, for nicotine dependence, the
CIDI.
(a) Lifetime Tobacco Use and Nicotine Dependence. The
SSAGA-OZ includes the CIDI assessment of nicotine de-
pendence. The test-retest reliability of the CIDI assessment
of nicotine dependence has been estimated at 0.64 (World
Health Organization, 1994). Items from the Heaviness of
Smoking Index (Heatherton et al., 1989)were also included.
(b) Lifetime Alcohol Use, Abuse, and Dependence. The
SSAGA-OZ, previously used in telephone interviews of
older cohorts of Australian twins ascertained using iden-
tical procedures to those currently proposed, obtains an
extensive lifetime history of the frequency of alcohol con-
sumption and the experience of symptoms of alcohol abuse
and dependence.
(c) Lifetime Use, Abuse, and Dependence on Other Illicit
Drugs. DSM-IV criteria for these drug classes were also
assessed using the SSAGA, which obtains full DSM-IV di-
agnostic criteria for abuse and dependence. SSAGA-based
assessments of dependence on these substances have accept-
able to good reliability and validity. Again, the reduced reli-
ability and validity of SSAGA assessments of abuse on these
substances is consistent with the estimated reliability and
validity of other assessments of abuse on these substances
and likely reflects limitations of the DSM operationaliza-
tions of abuse. Drug classes assessed included: (a) sedatives;
(b) cocaine; (c) amphetamines and other stimulants; (d)
opioids; (e) hallucinogens; (f) disassociates (phencyclidine,
ketamine); (g) solvents; and (h) inhalants.
(d) Lifetime Access and Availability of Cannabis and Other
Illicit Drugs. Exposure opportunity was assessed using pro-
cedures developed for earlier waves of the National House-
hold Survey and discussed by Anthony and colleagues
(Wagner & Anthony, 2002; Wilcox et al., 2002). Such ques-
tioning would precede questioning on drug use (including
licit drugs) and would involve respondents reporting the
age (if any) at which they first had access to each drug class
(including cannabis, other illicit drugs, and the licit drugs
tobacco and alcohol), irrespective of whether they used it at
that occasion or not.
(e) Lifetime Psychopathology. The SSAGA was designed
to collect comprehensive diagnostic informationon lifetime
patterns of psychiatric illness. For the current study, the
SSAGA provided the basis of DSM-IV assessments of the
following psychiatric disorders:
(a) Childhood conduct disorder.
(b) Adult antisocial personality disorder.
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(c) MDD.
(d) Suicidal ideation and attempted suicide.
(f) Childhood and Family Environment. A range of mea-
sures of childhood and family environment were also as-
sessed retrospectively including family history of substance
use and psychiatric disorders, parent–child relationships,
and parental discipline and current affiliations with delin-
quent or substance using peers.
(g) Zygosity. Twin pair zygosity was determined on the
basis of responses to standard questionnaires about physical
similarity and confusion of the twins by parents, teachers,
and strangers: methods that have been found to give better
than 95% agreement with results of genotyping. Informa-
tion about shared early experiences (e.g., sharedpeers, being
in the same classes at school)was also gathered to allow con-
servative adjustment for excess similarity of environmental
experiences in monozygotic (MZ) compared to dizygotic
(DZ) peers.
Use of a Computer-Assisted Telephone Interview
(CATI)
A feature of the current study was that it utilized a CATI.
Compared to hard paper copy interviews, CATI-based as-
sessment has a number of advantages including: (a) min-
imizing interviewer errors that may lead to subject recon-
tacts ormissing data; (b) improved querying of respondents
about their symptomhistories, through visual display to the
interviewer; (c) rapid editorial review to respond to inter-
viewer queries and provide interviewer feedback; (d) rapid
consultation of the project clinician to resolve diagnostic
questions: (e) ease of access to interviewer comments where
these may help resolve diagnostic and other issues (whereas
these are recorded in hardcopy interviews, they are rarely
accessed, especially in international collaborations); (f) as
a consequence of (e), greater ease of making data freely
available to other investigators. The average length of the
interview was 98 minutes.
Quality Control Steps
The CATI program contained numerous internal edits pre-
venting incorrect ormissing entries from recorded in the in-
terview. Internal programming also ensured that interview-
ers automatically ‘skipped’ to the next appropriate question.
Interviewers received substantial training and feedback on
their performance and attended monthly project meetings.
Each interview was audiotaped (subject to participant con-
sent) and project editors reviewed one in every 15 inter-
views. Feedback on these reviews was provided to inter-
viewers.
Statistical Analyses
Descriptive statistics and chi-square tests of association
were conducted in SAS (SAS Institute, 1999). Cox pro-
portional hazards models were fitted to the data to ex-
amine the relationship between age at first cannabis use
TABLE 3





Married or de facto relationship 53.8%




Both parents born in Australia 67.0
Education 8–10 years 6.5





Post graduate education 19.8












and age at opportunity to use cocaine in STATA (Stata
Corp, 2003) using stcox. The Huber–White variance es-
timator that adjusts standard errors for familial cluster-
ing was implemented. Univariate twin analyses were con-
ducted in Mx (Neale, 2004) using raw ordinal data and
full-information maximum-likelihood (FIML) estimation
which makes use of incomplete twin pairs. Variance was
attributed to additive genetic (A), shared environmental
(C), and unique/nonshared environmental (E, also includ-
ing measurement error) factors, with no evidence, based
on MZ–DZ correlations for nonadditive genetic (D) influ-
ences. Sex differences in prevalences or multiple response
categories weremodeled by allowing thresholds to differ be-
tweenmales and females. Even if these are the same between
sexes, it does not necessarily follow that causes of variation
in underlying liability will be the same inmales and females
and we also modeled this sex limitation by allowing the A,
C, and E parameters to vary across sexes, including allowing
for qualitative sex differences (Rg = 0.5) in DZ opposite sex
pairs.
Results
(1) Sample Characteristics. Demographic characteristics of
the final sample (including both twins and siblings) are
displayed in Table 3. More women than men participated,
which is typical of twin studies. The sample was predom-
inantly young adult with a high degree of educational at-
tainment with only 6.5% reporting less than a high school
education and 47.3% reporting some university education.
Nearly 83% of the sample was employed either full- or part-
time at the time of interviews.
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TABLE 4
Measures of Lifetime Cannabis use (%) and Symptomatology in
Males and Females (n = 3824) - Odds Ratios for Males







Opportunity to use 93.5 86.2 2.30 1.81–2.94
Lifetime use 75.2 64.7 1.66 1.43–1.92
Used 100+ times 23.0 11.3 2.33 1.95–2.78
Used weekly 29.1 16.8 2.03 1.74–2.38
Used daily 14.5 7.1 2.23 1.79–2.76
Cannabis abuse 23.3 10.6 2.58 2.15–3.08
Any DSM-IV dependence
symptom
23.7 12.7 2.12 1.79–2.52
DSM-IV Cannabis
dependence
14.8 6.8 2.40 1.93–2.97
Cannabis abuse/
dependence
24.5 11.8 2.44 2.05–2.90
(2) The Prevalence and Extent of Cannabis Involvement.
Note that, 75.2% of males and 64.7% of females re-
ported lifetime use of cannabis. When stratifying by com-
plete/incomplete twin pairs, cannabis use was elevated in
female twins whoseMZ co-twin orDZ opposite sex co-twin
did not participate.While 59.8%and 64.0%of females from
complete MZF and DZOS pairs reported lifetime cannabis
use, respectively, 68.9%and75.9%of singleton female twins
from these zygosity groups reported lifetime cannabis use
(p < .05). This pattern is expected if the variable in question
is affecting compliance rate; fortunately FIML corrects for
this ascertainment bias to give good estimates for the full
population (Neale & Cardon, 1992; Neale et al., 1994). No
other differences across zygosity groups were noted. While
many individuals reporting lifetime cannabis use had used
the drug relatively infrequently, prolonged, frequent, and
problematic cannabis usewas also relatively common in this
cohort: as shown in Table 4: 23.0% of men and 11.3% of
women reported using cannabis at least 100 times, 14.5% of
men and 7.1%ofwomen reported using it daily during their
period of heaviest use, 23.3% of men and 10.6% of women
met DSM criteria for cannabis abuse, and 14.8% (males)
and 6.8% (females) met lifetime criteria for cannabis de-
pendence. Across all these measures there were significant
sex differences with some suggestion that the magnitude
of these differences increased with increasing severity of
cannabis involvement: for example, males were 1.66 (95%
CI = 1.43–1.92) times more likely to report lifetime use
but 2.44 (95% CI = 1.05–3.90) times more likely to meet
criteria for cannabis abuse or dependence.
Of those reporting using cannabis at least 100 times,
48.5% met criteria for cannabis withdrawal as proposed
by DSM-5 (i.e., experiencing 3 or more of 7 withdrawal
symptoms) while 21.2% reported using withdrawal relief.
Table 5 shows the prevalence of these withdrawal symptoms
(considered to be endorsed if the respondent reported expe-
riencing it some, quite a bit, or a great deal) which ranged
from 47.4% for anger/aggression/irritability to 30.6% for
decreased appetite. Craving during abstinence, which is not
TABLE 5
Prevalence of Withdrawal Symptoms, as Proposed by DSM-5,
in Those Reporting Use of Cannabis at Least 100 Times Across
the Lifetime (n = 595)
Withdrawal symptom Prevalence (%)






Physical symptoms (headaches, shakes, stomach pain,
sweats)
32.8
part of the proposed DSM-5 revisions, was endorsed by
53.4%. Additionally, 37.3% endorsed experiencing nausea
or strange dreams. Withdrawal correlated well with other
DSM-IV abuse and dependence criteria (r = 0.66, Cron-
bach’s alpha = 0.81, total alpha = 0.83). In those who re-
ported using cannabis at least 100 times, 60.4% of those
meeting criteria for DSM-IV abuse or dependence also met
criteria for DSM-5 proposed withdrawal.
(3) Comorbidity Between Extent of Cannabis Involvement
and Other Substance Use and Psychiatric Disorders. Table 6
shows the associations between the extent of cannabis use,
assessedusing a three-level variable distinguishingnonusers
from lifetime users who either did or did not meet criteria
for a diagnosis of cannabis abuse or dependence. Several
features of the results displayed in this table are notewor-
thy: (a) there were particularly strong associations between
cannabis involvement and other measures of substance in-
volvement including dependence on the licit drugs (to-
bacco, alcohol) and illicit drug abuse/dependence. Similarly,
there were consistent albeit less strong associations between
cannabis involvement and measures of both externalizing
behaviors (including a history of childhood conduct dis-
order, attention defict hyperactivity disorder (ADHD), and
problem gambling) and internalizing behaviors (MDD, sui-
cidal behaviors, anxiety disorders). In all comparisons those
who met criteria for cannabis abuse or dependence had the
highest risks of these disorders and nonusers had the lowest
levels while individuals who reported having used cannabis
but who did meet criteria for cannabis abuse/dependence
having rates of these outcomes that were intermediate be-
tween these extremes.
(4)Age of Onset of Cannabis Use and Subsequent Cannabis
and Other Illicit Drug Involvement. A major focus of this
project concerned the extent to which early onset cannabis
use may be associated with escalation in drug use and the
development of illicit drug abuse/dependence. To explore
the utility of the current data for addressing these issues,
we present here a series of analyses describing the age of
onset of cannabis use and the links between early onset
cannabis use and later risks of other illicit drug use and drug
abuse/dependence.Onset of cannabis use typically occurred
during the teenage years with 78% of lifetime cannabis
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TABLE 6
Extent of Cannabis Involvement and Comorbidity with Substance Use and Other Psychiatric Disorders by Sex (n = 3,824)
Males [n = 1,389] Females [n = 2,435]
No use Use
Abuse/
dependence Phi∗ No use Use
Abuse/
dependence Phi
Nicotine dependence 7.3 22.3 59.7 0.43 5.9 28.3 62.6 0.40
Alcohol dependence 14.6 35.4 53.8 0.29 6.2 23.1 41.6 0.29
Other illicit drug abuse/dependence 2.0 5.8 41.2 0.46 0.6 5.7 33.9 0.39
Conduct disorder 5.0 10.4 30.9 0.28 1.2 4.3 22.7 0.29
ADHD 7.8 8.4 14.4 0.09 5.2 5.9 15.7 0.13
Problematic gambling 10.6 13.7 23.2 0.13 2.1 4.8 10.8 0.13
MDD 10.4 14.6 27.7 0.18 23.1 28.1 48.3 0.17
Suicidal ideation 16.8 23.1 42.9 0.22 20.6 25.6 46.9 0.18
Suicide attempt 1.7 1.5 6.8 0.14 3.2 5.0 13.6 0.14
Deliberate self-harm 3.1 3.9 12.9 0.17 4.3 7.9 17.8 0.15
Panic disorder 2.2 2.8 5.0 0.06 NS 4.6 5.7 12.2 0.10
Social phobia 1.1 1.7 3.5 0.06 NS 4.5 4.7 9.4 0.07
Note: ∗Phi coefficient of association, where φ = √(χ2/n). For two binary measures (2 × 2 contingency table), it approximates a Pearson

























Age of onset of cannabis use and rates of illicit drug use and cannabis/other illicit drug abuse/dependence (other abuse/dependence
includes cocaine, stimulants, & hallucinogens abuse/dependence) in 2,601 cannabis users.
users reporting initiating use before age 20. Again, there
was evidence of very small sex differences with early onset
of cannabis use being more common among males than
among females: for example, 57.5% of male cannabis users
reported initiating cannabis use before age 18, compared
with 50.9% of females.
Figure 1 shows the associations between age of onset of
cannabis use (measured as an ordinal variable) and mea-
sures of cannabis abuse/dependence, lifetime use of selected
illicit drugs (cocaine, stimulants, hallucinogens), and abuse
or dependence on these drug categories. This figure shows
consistent — and approximately linear — associations be-
tween the age of onset of cannabis use and risks of these out-
comes: individuals reporting onset of cannabis use before
age 16 had rates of these outcomes that were substantially
higher than rates among those initiating cannabis use after
age 20. Rates of these outcomes were lowest among those
reporting no lifetime use of cannabis.
(5) Age of Onset of Cannabis Use and Access/Opportunity
to Use Other Drugs. One key hypothesis described in our
initial grant (and based on previous work of Anthony and
colleagues; Wagner & Anthony, 2002) was that the links
between early onset cannabis use and later drug use may
potentially be explained by use of cannabis being associated
with increased availability and opportunity to use other
drugs. To examine this, we conducted a series of survival
analyses in which age of onset of opportunity to use co-
caine was modeled as a function of age of onset of cannabis
use, divided into the five categories described above: onset
before age 16, onset at ages 16, 17, onset at ages 18, 19,
onset at age 20 or older, and no lifetime cannabis use. These
results are summarized graphically in Figure 2 and show
a strong association between the age of onset of cannabis
use and the age at which subjects reported first having the
opportunity to use cocaine (whether or not they did, in
fact use cocaine then -– or indeed ever) (HR = 0.74, 95%
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Hazards of cocaine exposure opportunity as a function of varying age at first use (onset) of cannabis use in 2,601 cannabis users.
CI = 0.69–0.79). Thus, the earlier an individual used
cannabis for the first time, the lower the age at which they
first had the opportunity to use cocaine.
(6) The Heritability of Cannabis-Related Phenotypes. As
an initial attempt to examine the extent to which cannabis-
related phenotypes are influenced by heritable factors a
series of univariate geneticmodelswere fitted to the data on:
(a) early (≤15 years) opportunity to use cannabis; (b) early
onset (≤16 years) use; (c) lifetime use of cannabis on 11 or
more occasions, and (d)meetingDSM criteria for a lifetime
diagnosis of cannabis abuse or dependence. For each of
these phenotypes, the best-fitting model was one which
assumed no sex differences in the magnitude of genetic
or environmental effects and the results of these analyses
are summarized in Table 7. It can be seen that there were
substantial heritable influences on each of the cannabis-
related phenotypes with the magnitude of these influences
ranging from 72% (for both early onset opportunity to use
and DSM abuse/dependence) to 80% (for early onset use).
The best-fitting model was an AE model and there was no
significant evidence for shared environmental influences on
any of these measures.
TABLE 7
Estimated Heritability of Selected Cannabis-Related
Phenotypes
A C E
Early (≤15 years) opportunity to use 72 28
(63–80) (20–38)
Early onset (≤16 years) use 80 – 20
(73–86) (14–27)
Used 11+ times 76 – 24
(68–82) (18–32)
DSM abuse or dependence 72 – 28
(59–82) (18–41)
Discussion
In this paper, we have presented preliminary results from
an interview study of 3,824 Australian-born twins and their
nontwin siblings which included comprehensive assess-
ments of cannabis-related phenotypes and relatedmeasures
of substance use and psychiatric disorders. A striking find-
ing from the current study was the high levels of cannabis
involvement: some lifetime use of the drug was normative
with 64.7% of females and 75.2% of males reporting ever
having used the drug. These rates of use modestly exceeded
rates from an independent cohort of Australian twins born
between 1964 and 1971 (Lynskey et al., 2002) indicating
increasing use of cannabis in Australia for cohorts born
before 1990, consistent with prior findings from the Aus-
tralian Household Survey (Degenhardt et al., 2000). While
the majority of those reporting cannabis use had used the
drug only infrequently, there were substantial minorities
who reported frequent use or experiencing problems as a
consequence of their cannabis use. Strikingly, 11.8% of fe-
males and 24.5%ofmalesmet criteria forDSM-IV cannabis
abuse and/or dependence.
Again confirming the results of previous studies, there
was a high degree of association or comorbidity between
the extent of cannabis involvement and measures of other
substance use and abuse/dependence and psychiatric ill-
ness. Individuals who met criteria for cannabis abuse or
dependence had rates of these disorders that were 1.8–56.5
times higher than the corresponding rates among individ-
uals who reported never using cannabis (see Table 5) while
individuals who had used cannabis but did meet criteria
for abuse or dependence having rates of these outcomes
that were intermediate between these two groups. Multiple
explanations have been advanced to explain the associa-
tions between cannabis use and other drug use/psychiatric
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morbidity including that cannabis use -– and particularly
heavy or symptomatic use — predisposes individuals both
to use other substances and to develop substance use dis-
orders and other psychiatric disorders. Thus, for example,
it has been proposed that early onset cannabis use may in-
crease risks for the development of MDD among women
(Patton et al., 2002), Alternatively, it has been suggested that
drug usemaydevelop as a result of attempts to self-medicate
adverse emotional states (Khantzian, 1997). Finally, it has
also been proposed that there may be no patterns of re-
ciprocal causation between drug use and mental health but
that their apparent comorbidity arises from the influence of
shared and correlated risk factors that operate to increase
risks of both drug use and of mental health problems. For
example, ourown research, basedonanolder cohort ofAus-
tralian twins, suggests that the associationbetween cannabis
use and depressionmay be largely noncausal and arise from
risk factors, particularly shared genetic predispositions that
increase risks of both cannabis use and of developingmajor
depression (Lynskey et al., 2004). While we have not ex-
amined mechanisms underlying the observed associations
between cannabis use and other drug use/mental health in
our current analyses, we hope to more fully exploit the ad-
vantages of twin data to more comprehensively address this
question using the current data set.
The current analyses also demonstrated a strong inverse
relationship between age of onset of cannabis use and risks
of a range of drug-related outcomes including use of (other)
illicit drugs and development of abuse or dependence on
cannabis, other illicit drugs, and on the licit drugs tobacco
and alcohol (Figure 1). For example, 36.8% of those who
reported using cannabis before age 16 reported lifetime
use of cocaine, compared with only 13.2% of those who
commenced cannabis use after age 20 (and 1.1% of those
who reported never using cannabis). Additionally, the as-
sociation between age of onset of cannabis use and these
outcomes was approximately linear with risks of these out-
comes increasing steadily as age of onset of cannabis use
declined. While such associations have commonly been re-
ported in the literature, they remain controversial and, in
particular, interpretation of these associations and of the
mechanisms underlying them remains a topic of consider-
able debate. In addition to the advantages to studying this
important question inherent in the twin design, the current
study also contained several unique aspects of data collec-
tion that we hope will help elucidate these mechanisms.
Preliminary analyses presented here, while not comprehen-
sively addressing this, do suggest that more intensive anal-
yses of the data collected here may offer valuable insights
into themechanisms underlying these associations. Specifi-
cally, our data highlight the important associations between
age of onset of cannabis use and increasing opportunities
for the use of other illicit drugs. In future studies based
on these data, we hope to explore the extent to which the
well known associations between declining age of onset of
cannabis use and increasing rates of other illicit drug use
and drug abuse/dependence can be explained by a combi-
nation of factors including opportunity and access to other
drugs as well as peer and related factors. Resolution of this
issue has important implications for policy and prevention
of substance-related problems.
Finally, the importance of studying such policy relevant
questions within the context of genetically informative re-
search designs was highlighted by our findings of consider-
able heritable influences across a range of cannabis-related
phenotypes including those, such as opportunity to use
cannabis, that have been traditionally perceived as envi-
ronmental constructs. Nonetheless, our analyses revealed
moderate heritable influences on both early age of first op-
portunity to use cannabis use (72%) and, importantly, on
early onset cannabis use itself (80%). In parallel analyses,
we also found evidence for moderate to high heritability of
a measure of cannabis abuse or dependence. While there
were differences between the current study and previous
studies of cannabis abuse/dependence (e.g., cohort differ-
ences between samples, the inclusion of a comprehensive
assessment of withdrawal within the definition of depen-
dence), the parallels between our findings and those of pre-
vious studies are striking and there is now a convergence of
evidence to suggest that between 51% and 58% of liability
to develop cannabis dependence within Western societies
where cannabis is commonly available can be attributed to
heritable influences (Verweij et al., 2010). It therefore re-
mains feasible that some component both of the association
between age of onset of cannabis use and the subsequent
use and misuse of other illicit drugs and of the comor-
bidity between cannabis dependence and other psychiatric
conditions (including drug dependence) may be due to a
shared genetic liability between cannabis use/dependence
and these other phenotypes. In subsequent studies based
on these data, we hope to able to help elucidate such
issues.
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